NYSE:ISR Isoray (ISR) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free ISR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.28▼$0.4252-Week Range N/AVolume145,000 shsAverage Volume290,697 shsMarket Capitalization$54.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Isoray alerts: Email Address Ad Weiss Ratings[Urgent] Protect your money before NovemberDo you feel like something strange is happening in America? Every day, hundreds of thousands of military-aged men are pouring through our broken borders … I share all the details about what's happening, and give you the three steps I feel you must take to prepare yourself — RIGHT NOW.Click here to watch now. About Isoray Stock (NYSE:ISR)IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.Read More Ad Weiss Ratings[Urgent] Protect your money before NovemberDo you feel like something strange is happening in America? Every day, hundreds of thousands of military-aged men are pouring through our broken borders … I share all the details about what's happening, and give you the three steps I feel you must take to prepare yourself — RIGHT NOW.Click here to watch now. ISR Stock News HeadlinesNovember 22, 2023 | morningstar.comFrench ISR Label Revamp ReportApril 24, 2023 | thestreet.comWhy IsoRay (ISR) Is Plunging TodayJune 18, 2024 | Behind the Markets (Ad)This Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!March 16, 2023 | thestreet.comWhy IsoRay (ISR) Stock Is Surging TodayFebruary 16, 2023 | finance.yahoo.comIsoRay (ISR) Reports Q2 Loss, Misses Revenue EstimatesFebruary 16, 2023 | finance.yahoo.comPerspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022February 8, 2023 | finanznachrichten.deIsoray, Inc.: Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.February 7, 2023 | finance.yahoo.comIsoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.June 18, 2024 | Weiss Ratings (Ad)[Urgent] Protect your money before NovemberDo you feel like something strange is happening in America? Every day, hundreds of thousands of military-aged men are pouring through our broken borders … I share all the details about what's happening, and give you the three steps I feel you must take to prepare yourself — RIGHT NOW.February 6, 2023 | finance.yahoo.comIsoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology MedicineJanuary 30, 2023 | benzinga.comIsoray Announces Results of Fiscal 2023 Annual Meeting of StockholdersJanuary 30, 2023 | finance.yahoo.comIsoray Announces Results of Fiscal 2023 Annual Meeting of StockholdersJanuary 14, 2023 | thestreet.comWhy IsoRay (ISR) Hit a Five-Year High Today (Update)January 12, 2023 | finance.yahoo.comIsoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023December 14, 2022 | finance.yahoo.comIsoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2022December 14, 2022 | finance.yahoo.comAMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023December 6, 2022 | proactiveinvestors.comIsoray's merger with Viewpoint Molecular Targeting sets up big opportunity in 2023December 6, 2022 | proactiveinvestors.comIsoray releases Q1 financials as company looks ahead to merger with Viewpoint Molecular TargetingNovember 25, 2022 | finance.yahoo.comIsoray, Inc. (ISR) Stock Historical Prices & Data - Yahoo FinanceNovember 11, 2022 | finanznachrichten.deIsoray, Inc.: Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending MergerNovember 10, 2022 | seekingalpha.comIsoray, Inc. (ISR) Q1 2023 Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comIsoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending MergerOctober 31, 2022 | finance.yahoo.comIsoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022October 20, 2022 | seekingalpha.comIsoray Stock: Not Going Anywhere Anytime Soon (NYSE:ISR) - Seeking AlphaOctober 18, 2022 | businesswire.comIsoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT - Business WireOctober 18, 2022 | finance.yahoo.comIsoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDTOctober 16, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, ISR, JVA - Isoray (AMEX:ISR), BTRS H - BenzingaSee More Headlines Receive ISR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today6/18/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:ISR CUSIPN/A CIK728387 Webisoray.com Phone(509) 375-1202Fax509-267-3670EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,270,000.00 Net Margins-115.91% Pretax Margin-91.45% Return on Equity-17.12% Return on Assets-16.15% Debt Debt-to-Equity RatioN/A Current Ratio14.38 Quick Ratio13.99 Sales & Book Value Annual Sales$10.80 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / BookN/AMiscellaneous Outstanding Shares142,110,000Free Float138,674,000Market Cap$54.57 million OptionableNot Optionable Beta1.48 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesLori A. WoodsChief Executive Officer & DirectorJennifer StreeterChief Operating Officer & VP-Human ResourcesMark J. AustinCo-CFO, Secretary & Chief Accounting OfficerJonathan R. HuntCFO & Principal Financial OfficerWilliam A. CavanaghChief Research & Development OfficerKey CompetitorsCVRxNASDAQ:CVRXAVITA MedicalNASDAQ:RCELDelcath SystemsNASDAQ:DCTHProfound MedicalNASDAQ:PROFNyxoahNASDAQ:NYXHView All Competitors ISR Stock Analysis - Frequently Asked Questions How were Isoray's earnings last quarter? Isoray, Inc. (NYSE:ISR) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The company earned $2.56 million during the quarter, compared to analyst estimates of $2.58 million. Isoray had a negative trailing twelve-month return on equity of 17.12% and a negative net margin of 115.91%. This page (NYSE:ISR) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Isoray, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Isoray With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.